WO2023014853 - HPV VACCINE
National phase entry:
Publication Number
WO/2023/014853
Publication Date
09.02.2023
International Application No.
PCT/US2022/039371
International Filing Date
04.08.2022
Title **
[English]
HPV VACCINE
[French]
VACCIN ANTI-VPH
Applicants **
MERCK SHARP & DOHME LLC
BETT, Andrew
BILELLO, John, P.
CEJAS, Pedro, J.
ESPESETH, Amy, S.
FU, Tong-Ming
STRABLE, Erica, L.
BARR, Colleen, M.
ZIMMERMANN, Sara
Inventors
BETT, Andrew
BILELLO, John, P.
CEJAS, Pedro, J.
ESPESETH, Amy, S.
FU, Tong-Ming
STRABLE, Erica, L.
BARR, Colleen, M.
ZIMMERMANN, Sara
Priority Data
63/230,426
06.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4520 | |
| EPO | Filing, Examination, Granting | 77706 | |
| Japan | Filing, Examination, Granting | 4531 | |
| South Korea | Filing, Examination, Granting | 6393 | |
| USA | Filing, Examination, Granting | 22140 |
Total:
115,290
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides, among other things, a single-dose vaccine composition that includes a chitosan adjuvant and HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82, where the single-dose vaccine composition provides enhanced or comparable HPV vaccine response in comparison to a similar multiple-dose vaccine formulated without such chitosan adjuvant.[French]
La présente divulgation concerne, entre autres, une composition de vaccin à dose unique qui comprend un adjuvant de chitosane et des particules de type virus VPH (PPV) d'au moins un type de papillomavirus humain (VPH) choisi dans le groupe constitué par les types de VPH : 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73 et 82, la composition de vaccin à dose unique fournissant une réponse de vaccin VPH améliorée ou comparable par rapport à un vaccin à dose multiple similaire formulé sans un tel adjuvant de chitosane.